Table 4
(a) Summary of major cell-based clinical trials

StudyMethod of deliveryPatients treated/controlPlacebo/controlCell type cell/number or doseTime of cell delivery (days after MI)Results

Strauer et al., 2002 [114] (Germany)IC20/10Case controlledBM-MNC
9–28 × 106
7Improved contractility and reduced infarct size at 6 months

TOPCARE-AMI, Assmus et al. 2002 [117], Schächinger 2004 [118]
(Germany)
IC30/29Control Nonrandomized open-labeled BM-MNC
2.4 × 108
CPC 1.3 × 107
3 to 7Improved LVFE and reduced infract size at 4–12 months

BOOST,
Wollert et al. 2004 [119],
IC30/30ControlBM-MNC
24 × 109
6Improved EF at 6 months, increased regional contractility,
Meyer et al. 2006 [125]
(Germany)
no difference at 18 months

REPAIR-AMI,
Schächinger et al.
2006 [123] (Germany)
IC102/102PlaceboBM-MNC
2.4 × 108
4Improved EF and reduced infarct size at 4 months

Fernandez et al. 2004 [120]IC20/13ControlBM-MNC
11–90 × 106
10–15Significant functional improvement and reduced infarct size

Janssens et al., 2005 [122] (Belgium)IC33/34PlaceboBM-MNC
3.0 × 108 cells
1Decrease scar size but no improvement in LVEF at 4 months

ASTAMI, lunde et al. 2006 [124] (Norway)IC50/50Control
Randomized + placebo controlled
BM-MNC
8.7 × 107
5 to 8No difference at 6 months

Shah et al. 2007 [121, 126] (India)IC20/10Control
Open-label nonrandomized
BM-MNC
13.4 × 107
6 to 8Improved LV function at 6 months and sustained at 24 months

Chen et al. 2004 [127] (China)IC34/35Placebo
Controlled
MCSs
48–68 × 1010
18Inc LVEF, Inc regional contractility, increase viability of infarct zone/wall after 3 and 6 months

Hare et al. 2009 [129] (USA)IV39/21Double-blind placebo controlledMSCs 0.5, 1.6, 5 million cells/kg1, 2, 3, 6 months followupImproved LVEF and reverse modeling

IC: intracoronary, IV: intravenous, BM-MNC: unfractionated bone marrow mononuclear cells, CPC: Circulating progenitor cells, MSCs: mesenchymal stem cells.
(b) Summary of major cell-based clinical trials

Study Method of deliveryPatients treated/controlled Placebo/control Cell type, cell number, or doseTime of cell delivery (days after MI) Results

Ince et al. 2005 [152] First Line-AMI (Germany)Mobilization of G-CSF15/15Randomized + controlledBM-MNC CD34+1–6After 4 and 12 month followup improved LVEF and systolic wall thickness

Ripa et al. 2006 [153],
STEMMI (Denmark)
Mobilization of G-CSF39/39Randomized + placebo controlledBM-MNC CD34+1–6After 6 month followup systolic wall thickness viability of infarct zone/wall
Zohlnhöfer et al. 2006 [154], REVIVAL (Germany)Mobilization of G-CSF56/58Randomized + placebo controlledBM-MNC CD34+1–6After 4 and 6 month followup No effects

Engelman et al. 2006 [155],
G-CSF-STEMI (Germany)
Mobilization of G-CSF22/22Randomized + placebo controlledBM-MNC CD34+1–5After 4 and 6 month followup
No effects